Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0906 • ACR Convergence 2024
Proteomic Signatures of Difficult-to-Treat Rheumatoid Arthritis: Identifying Predictive Biomarkers
Klára Mocová¹, Jiri Baloun¹, Aneta Prokopcová², Kristýna Brábníková Marešová¹, Herman Mann³, Jiří Vencovský², Karel Pavelka⁴ and Ladislav Šenolt², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Revmatologický ústav, Praha, Czech Republic, ⁴Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction and extra-articular manifestations. Despite the advancements in the…
Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abhishek Abhishek¹, Nicholas Peckham² and Jonathan Cook², and the VROOM Study Author Group, ¹University of Nottingham, Nottingham, United Kingdom, ²Oxford University, Oxford, United Kingdom
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…
Abstract Number: 1023 • ACR Convergence 2024
Factors Associated with Delays in Dispensation and Insurance Denials of Janus Kinase Inhibitors
Igor Dombrovsky¹, Michael George², Joshua Baker² and Thomas Riley³, ¹Pennsylvania Hospital, Philadephia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Hopsital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Access to Janus kinase inhibitors (JAKi) is controlled by insurance carriers through prior authorizations and the use of restricted formularies. We previously showed that…
Abstract Number: 1130 • ACR Convergence 2024
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Melanie Hagen¹, Laura Bucci¹, Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
Abstract Number: 1332 • ACR Convergence 2024
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Amber Brown Keebler¹, Yunju Im², Sofia Pedro³, Ted Mikuls¹, Edward Peters¹ and Kaleb Michaud¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
Abstract Number: 1349 • ACR Convergence 2024
Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis
Jasmine Sim¹, Nandhini Ramamoorthi², Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Anna Guttman⁴, Andrew Melville⁵, Nisha Rathore², Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Andrew Filer⁷, Karim Raza⁷, Christopher Buckley⁸, Arthur Pratt¹, James Wason⁹, Amy Anderson¹, Michael Townsend², Kenneth Baker¹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Genentech, South San Francisco, CA, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Genentech, South San Franscisco, CA, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁹Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
Abstract Number: 1365 • ACR Convergence 2024
Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings
Hui Yu¹, Puran Nepal², Laura Daniel³, Marco Barbero Mota⁴, Gul Karakoc⁵, Maria Carpintero¹, C. Michael Stein⁶, Cecilia P. Chung¹, Yan Guo¹ and Vivian K. Kawai⁶, ¹University of MIami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³University of Miami, Nashville, TN, ⁴Vanderbilt University, Nashville, TN, ⁵Vanderbilt University Medical Center, Mt. Pleasant, SC, ⁶Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a multisystem disease with a strong genetic component and multiple comorbidities. Genome wide association studies (GWAS) have identified single nucleotide…
Abstract Number: 1382 • ACR Convergence 2024
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Yangsu Ren¹, Catherine Aversa¹, Myles Lewis², Cankut Cubuk³, Felice Rivellese⁴, Liliane Fossati-Jimack³, Pejman Soroosh¹, Amy Archer¹, Martin Dahl¹, Paul Lizzul¹, Cailin Sibley¹ and Costantino Pitzalis⁵, ¹AnaptysBio, San Diego, CA, ²Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ⁴Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵QMUL, Bromley Kent, United Kingdom
Background/Purpose: Despite multiple approved therapies in rheumatoid arthritis (RA), many patients do not achieve clinically meaningful responses, emphasizing the need for novel therapeutics with improved…
Abstract Number: 1398 • ACR Convergence 2024
Difficult to Treat Rheumatoid Arthritis Incidence and Risk Factors in the Early Arthritis UCLouvain Brussels Cohort
NATALUCCI Francesco¹, Clément triaille², SAPART Emilie³, DIERCKX Stéphanie⁴, VAN MULLEM Cécile³, de MONTJOYE Stéphanie³, SOKOLOVA Tatiana³, AVRAMOVSKA Aleksandra³ and DUREZ Patrick³, ¹Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, ²Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, Brussels, Belgium, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Bruxelles, Belgium
Background/Purpose: Over the past decades, the treatment of Rheumatoid Arthritis (RA) has significantly improved, making accessible therapeutic goals such as clinical and structural remission. However,…
Abstract Number: 1677 • ACR Convergence 2024
Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial
Ru Li¹, Xing Sun¹, Suping Niu², Xiaolin Sun¹, Guimin Zheng³, Meilu Liu³, Jiyang Lv⁴, Gengmin Zhou⁴, Gang Yuan⁵, Yujin Ye⁵, Shuang Wang⁵, Pingfei Fang⁶, Qi Tang⁶, Jin Kang⁶, Xiaoyue Li⁷, Chao Sun⁷, Song Zhang⁷, Yongjun Mei⁷, Jian Wang⁷, He Su⁷, Lijing Huang⁸, Chenhui Li⁸, Chao Liu⁸, Fengxiao Zhang³, Qingwen Wang⁴, Niansheng Yang⁵, Fen Li⁶, Linjie Chen⁷, Yi Fang² and Zhanguo Li⁹, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ²Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), ⁴Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), ⁵Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁸Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), ⁹Peking univeristy people's hospital, Beijing, China
Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
Abstract Number: 1748 • ACR Convergence 2024
Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Rachel Elam¹, Emma Kersey², Jing Li³, Gabriela Schmajuk⁴ and Laura Carbone⁵, ¹Augusta University, Evans, GA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Augusta University, Augusta, GA
Background/Purpose: Fracture incidence rates (IRs) are higher in men and women with rheumatoid arthritis (RA) than those without RA, especially for those with higher RA…
Abstract Number: 1890 • ACR Convergence 2024
Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study
Dani Contreras¹, Zanir Bhanji¹, J. Antonio Avina-Zubieta², Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Ambulatory Care Sensitive Conditions (ACSCs) are conditions where appropriate access to ambulatory care could prevent or reduce complications, a more severe disease course, or…
Abstract Number: 1978.5 • ACR Convergence 2024
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Faye Yu¹, Eugene Myshkin², Carolina Bobadilla Mendez³, Marta Cossu⁴, Kaiyin Fei⁵, Qingmin Wang⁶, Matthew J. Loza⁶, Dessislava Dimitrova³ and Sheng Gao³, ¹Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, USA, MA, MA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ⁴Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering IgG…
Abstract Number: 2211 • ACR Convergence 2024
Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques
Jiri Baloun¹, Lucie Andrés Cerezo², Tereza Kropáčková³, Aneta Prokopcova⁴, Kristýna Brábníková Marešová¹, Herman Mann⁵, Jiří Vencovský³, Karel Pavelka⁶ and Ladislav Šenolt³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴First faculty of medicine and Institute of Rheumatology, Charles University, Prague, Czech Republic, ⁵Revmatologický ústav, Praha, Czech Republic, ⁶Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Despite advances in biologic (b-) and targeted synthetic (ts-) disease-modifying anti-rheumatic drugs (DMARDs), a significant subset of rheumatoid arthritis (RA) patients remain symptomatic, meeting…
Abstract Number: 2229 • ACR Convergence 2024
Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination
Kaien Gu¹, Leanne Lac¹, Nathalie Carrier², Liam O'Neil¹, Gilles Boire³, Pingzhou Hu⁴ and Carol Hitchon¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴Western University, London, ON, Canada
Background/Purpose: Despite methotrexate (MTX) being the cornerstone of rheumatoid arthritis (RA) therapy, uncertainty exists around who will respond to MTX. We aimed to determine the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].